Patients with acute myeloid leukaemia Cancer Acute myeloid leukaemia
Conditions
Interventions
A single skin biopsy will be taken at time of Hickman Line insertion from the surgical site. Each patient will receive five days of Fludarabine followed by one dose of single fraction total body irrad
Sponsors
University College London
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All recipients will have a diagnosis of acute myeloid leukaemia (AML) and be in one of the following subgroups: 1. Patients aged > 60 years in PR (blasts >5 60 years with relapsed AML in CR2 after re-induction chemotherapy 3. Patients aged > 60 years in PR or CR after 2 courses of chemotherapy with poor risk disease using standard MRC criteria 4. Patients aged < 60 years beyond CR2 who are not suitable for stem cell transplantation with conventional or reduced intensity conditioning protocols
Exclusion criteria
Exclusion criteria: 1. HIV 1-2 seropositive 2. Psychiatric, addictive, or any disorder which compromises ability to give true informed consent for participation in this study 3. Pregnant or lactating women 4. Patients whose life expectancy is severely limited by illness other than for which they are undergoing immunotherapy 5. Patients with other active malignancy 6. Patients with known physical or religious sensitivity or prior exposure to murine and/or ovine proteins
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the safety of infusion of allogeneic, tumour-activated NK cells after low dose radiotherapy plus medium dose chemotherapy with respect to acute / chronic GvHD and bone marrow suppression | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To assess the quantitative and qualitative aspects of immune responses to acute myeloid leukaemia (AML) cells in these patients after NK cell infusion 2. To assess long term survival of donor NK cells in the peripheral circulation of recipients | — |
Countries
United Kingdom
Outcome results
None listed